Galmed reports significant anti-fibrotic effects of aramchol in a lung fibrosis model

Statistically significant clinical and histology improvements were also demonstrated in a model of inflammatory bowel disease (ibd) data reinforcing the expansion of aramchol's clinical development to additional indications   tel aviv, israel , july 7, 2022 /prnewswire/ -- galmed pharmaceuticals ltd. (nasdaq: glmd) ("galmed" or the "company"), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and inflammatory diseases, announced today results showing significant effects of aramchol in pre-clinical model of both lung and gastrointestinal (gi) fibrosis.
GLMD Ratings Summary
GLMD Quant Ranking